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OBJECTIVES: The objective of this study was to apply a pharmacokinetics-pharmacodynamics approach to
investigate the free propofol plasma levels in patients undergoing coronary artery bypass grafting under
hypothermic conditions compared with the off-pump procedure.
METHODS: Nineteen patients scheduled for on-pump coronary artery bypass grafting under hypothermic
conditions (n=10) or the equivalent off-pump surgery (n=9) were anesthetized with sufentanil and propofol
target-controlled infusion (2 mg/mL) during surgery. The propofol concentration was then reduced to 1 mg/mL,
and a pharmacokinetics-pharmacodynamics analysis using the maximum-effect-sigmoid model obtained by
plotting the bispectral index values against the free propofol plasma levels was performed.
RESULTS: Significant increases (two- to five-fold) in the free propofol plasma levels were observed in the
patients subjected to coronary artery bypass grafting under hypothermic conditions. The pharmacokinetics of
propofol varied according to the free drug levels in the hypothermic on-pump group versus the off-pump
group. After hypothermic coronary artery bypass was initiated, the distribution volume increased, and the
distribution half-life was prolonged. Propofol target-controlled infusion was discontinued when orotracheal
extubation was indicated, and the time to patient extubation was significantly higher in the hypothermic
on-pump group than in the off-pump group (459 versus 273 min, p=0.0048).
CONCLUSIONS: The orotracheal intubation time was significantly longer in the hypothermic on-pump group
than in the off-pump group. Additionally, residual hypnosis was identified through the pharmacokinetics-
pharmacodynamics approach based on decreases in drug plasma protein binding in the hypothermic on-pump
group, which could explain the increased hypnosis observed with this drug in this group of patients.
KEYWORDS: Coronary Artery Bypass; Cardiopulmonary Bypass; Propofol; Protein Binding; Pharmacokinetics;
Pharmacodynamics.
’ INTRODUCTION
Propofol is a hypnotic agent that is widely used in surgery
because of its interesting pharmacokinetic (PK) properties.
Target-controlled infusion (TCI) facilitates early orotracheal
extubation after surgery, which might contribute to reducing
the postoperative mechanical ventilation period, shortening
patients’ stays in the intensive care unit, lowering the
incidence of nosocomial infections, and reducing hospital
costs (1-3).
During coronary artery bypass grafting (CABG) surgery
with cardiopulmonary bypass (CPB), profound changes in
the effect of propofol and its kinetic behavior were observed
based on total drug plasma measurements in these patients.
As reported previously, drug plasma binding might be altered
due to hemodilution after normothermic CPB because the
free propofol plasma levels were increased (4-6). In addition,
TCI is recommended for maintenance of the propofol plasma
concentration (2 mg/mL) during CABG-CPB because its drug
effect is rapidly lost in the liver, mainly through the CYP2B6
pathway. This pathway produces 2,6 di-isopropylquinol and
2,6 di-isopropyl-1,4-quinol derivatives, which are conjugated
and excreted in the urine as quinol-1-glycuronide, quinol-4-
glycuronide, and quinol-4-sulfate (7).DOI: 10.6061/clinics/2018/e178
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However, whether the significant changes in propofol
hypnosis that occur in these patients are related to reduction
of the extension of drug plasma binding remains unclear (8).
Therefore, the objective of this study was to investigate the
free propofol plasma levels in patients undergoing CABG
with and without CPB using a PK-pharmacodynamics (PD)
approach.
’ MATERIALS AND METHODS
Nineteen patients were scheduled for elective cardiac sur-
gery. The characteristics of these patients, expressed as the
medians (quartiles), were as follows: age of 67.0 (61.5-69.5)
years, weight of 73.7 (65.5-80) kg, and a body mass index
(BMI) of 27.50 (25.12-29.42) kg/m2. The inclusion criteria
were a left ventricular ejection fraction exceeding 50% and
normal hepatic and renal function. The patients included in
the study were stratified into two groups based on the
surgeon’s criteria as follows: Group 1, on-pump CABG with
hypothermic (32-34oC) CPB (CPB-H, n=10); and Group 2,
off-pump CABG (OPCAB, n=09). During the transoperative
period, pre-anesthetic medication (midazolam: 0.2 mg/kg)
was administered orally in the operating room, and a routine
surgical protocol (previously detailed by the same authors)
was then performed for each patient investigated (8). During
the surgical intervention, hypnosis was achieved with pro-
pofol infusion to maintain a bispectral index (BIS) value of
40 based on a predicted plasma concentration of 2 mg/mL.
At the end of surgery, the predicted drug plasma level
was reduced to 1 mg/mL (DiprifusorTM, Astra-Zeneca,
Detroit, MI, USA). During the intervention, hypnosis and
hemodynamic parameters were monitored by anesthesiol-
ogists in the operating room throughout the transoperative
period.
During the period from admission to the operating room
until 12 hours after tracheal extubation, 3-mL blood samples
were collected for drug plasma measurements, and the BIS
was continuously monitored using a BISR XP device (Aspect
Medical Systems, Natick, MA, USA) for brain activity mea-
surements. The criteria for tracheal extubation were based on
the routine protocol of our hospital as described previously
by the same authors (8).
The blood samples were centrifuged to obtain plasma
for drug measurements, and the samples were stored in a
deep freezer (-80oC) until use. The propofol plasma samples
were analyzed using a validated bioanalytical method based
on high-performance liquid chromatography with fluores-
cence detection (HPLC-FD), as reported previously (7) for a
two-compartment open model PK study –Non-Compartmental
PK Data Analysis (Summit, USA). Ultrafiltration using
Amicon-Ultras (Millipore, Ireland) was applied to separate
bonded and free propofol from plasma samples. After puri-
fication of the biological matrix, the drug plasma level was
measured using the LC10 fluorescence detector RF10AXLs
(276/310 nm) (Shimazdu, Kyoto, Japan). The chromatographic
conditions consisted of a reverse phase column (ShimPacks
CLC – ODS C18 150 x 6.0 mm, 5 microns, Shimazdu, Kyoto,
Japan) and a binary mobile phase of acetonitrile and water
acidified with acetic to a pH of 4.6 (60:40, v/v). The mobile
phase was prepared daily, degassed under helium (99.9%)
strain and pumped isocratically at 0.8 ml/min, and each
run time was 25 min. This method demonstrated linearity
from 10 to 10.000 ng/mL, with a limit of detection of 5 ng/
mL and a linear regression coefficient of 0.9977.
The estimated PK parameters were hybrid rate constants
for drug distribution (a) and drug elimination (b) and their
respective half-lives (t(1/2)a and t(1/2)b). Non-compartmental
PK parameters, including drug plasma clearance (CLT) and
the apparent volume of distribution (VDSS), were estimated
by the area method.
In addition, PD was investigated by plotting the BIS values
versus time, and a PK/PD approach was implemented based
on a plot of the BIS values against the free propofol plasma
levels over time. The sigmoid EMAX model (variable slope)
was selected to represent the hypnotic effect of propofol
expressed by the BIS values as a function of the free drug
plasma level.
A nonparametric statistical analysis was performed based
on the Mann-Whitney U test, with the data expressed as
the medians (quartiles). P-values o0.05 were considered
statistically significant, and Prism v.5.0 software was used
(Inc., San Diego, CA, USA).
Ethics
The study protocol was approved by the Hospital Ethics
Committee, and written informed consent was obtained from
all included patients. All procedures were in accordance with
good clinical practices and Brazilian regulations.
’ RESULTS
Table 1 summarizes the demographic data of the indivi-
dual patients. The data regarding age, body weight, BMI,
and the duration of surgery were similar, as demonstrated
through the group comparison, whereas the time required
for orotracheal intubation differed significantly between the
groups. The duration of surgery was similar between the
patients subjected to either CPB-H (265 min) or OPCAB
(260 min, p=0.7747). In contrast, the time to extubation was
significantly longer for the patients receiving CPB-H (459
[301-526] min) than for the patients undergoing OPCAB
(273 [198-289] min) (p=0.0048; median [quartiles]). The
duration of the CPB procedure was 79 (64-95) min (median
[quartiles]).
A total of 994 blood samples were analyzed to obtain the
total and free plasma levels of propofol in the CPB-H (580
samples) and OPCAB (414 samples) patients. The median
infused doses in both groups were comparable: 1510 mg
(CPB-H) versus 1555 mg (OPCAB); p=0.2428. The total and
free plasma levels of propofol did not differ between the
groups throughout the study, as indicated in Table 2.
The PK of propofol based on the free plasma levels over
time analyzed using a two-compartment open model are
described in Table 3.
A comparison of the parameters of the two groups revealed
significant changes in the PK of propofol: the plasma clearance
and VDSS were increased in the CPB-H versus OPCAB groups
due to reduced drug plasma binding caused by CPB-H.
Consequently, the free propofol plasma levels of the CPB-H
patients were increased relative to those of the OPCAB
patients (Figure 1).
A PD approach based on measuring the drug effect over
time indicated that during the intra-operative period, BISp40
was achieved, and the data were comparable between the
groups. In contrast, after the drug infusion was reduced at the
end of surgery and subsequently discontinued, the BIS values
of the CPB-H patients were significantly lower than those of
the OPCAB patients (Figure 2).
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A PK/PD approach based on plotting BIS values against
free drug plasma levels indicated that during the post-
operative period, hypnosis in the CPB-H patients decreased
more slowly than that in the OPCAB patients due to an
increase in the free drug available to the receptor sites.
Although the propofol effect (expressed as the effective
free drug concentration required to attain 50% of the
maximum effect [EC50]) was comparable in both groups,
the PK/PD approach could explain the differences between
the groups based on the prolonged time to orotracheal intubation
Table 1 - Demographic characteristics of the individual patients and surgical data.
Patient allocation Gender (M/F) Age (yrs) BW (kg) BMI (kg/m2) Duration of surgery (min) Orotracheal intubation (min)
CPB-H OPCAB CPB-H OPCAB
1 M 67 66.0 23.9 270 292
2 M 64 92.5 34.4 230 287
3 F 74 63.0 28.0 270 232
4 M 56 84.0 32.8 310 292
5 F 67 78.0 27.4 330 238
6 M 59 65.0 22.8 235 534
7 M 74 65.0 23.3 325 549
8 F 52 71.0 33.3 260 198
9 F 69 76.0 26.5 225 519
10 M 67 72.6 29.5 390 330
11 M 68 76.2 27.7 300 450
12 M 66 90.0 29.3 205 289
13 M 56 65.0 25.4 260 468
14 M 49 90.0 35.2 230 528
15 M 72 73.7 27.5 220 339
16 M 70 64.8 23.6 210 378
17 M 68 82.0 28.1 255 273
18 M 75 71.0 25.2 330 186

















Patient allocation - CPB-H group: 1, 2, 4, 6, 7, 9, 10, 11, 13, 14; OPCAB group: 3, 5, 8, 12, 15, 16, 17, 18, 19. Abbreviations – N/A: not applicable; BW: body
weight; BMI: body mass index; F: female; M: male; CPB-H: on-pump coronary artery bypass grafting; OPCAB: off-pump coronary artery bypass grafting.
Statistics: Mann-Whitney test, GraphPad Prism v. 5.0, significance po0.05.
Table 2 - Propofol plasma levels over time.
Time of sampling Total propofol plasma levels (lg/mL), p40.05 Free propofol plasma levels (ng/mL), p40.05
Starts TCI CPB-H (n=10) OPCAB (n=9) CPB-H (n=10) OPCAB (n=9)
(min) Medians (quartiles) Medians (quartiles) Medians (quartiles) Medians (quartiles)
5 1.77 (1.09-2.89) 1.79 (1.63-2.59) 94.87 (48.96-160.92) 96.17 (73.92-179.52)
15 1.39 (1.11-1.98) 1.71 (1.45-3.03) 59.36 (52.00-109.65) 95.70 (66.88-164.70)
30 2.37 (1.79-2.99) 2.75 (2.03-3.42) 140.76 (88.20-153.70) 147.40 (75.11-161.67)
60 1.94 (1.21-2.55) 1.60 (1.35-2.51) 125.82 (69.75-146.88) 86.97 (59.20-138.05)
120 2.43 (1.92-3.04) 3.15 (2.42-3.61) 141.34 (103.35-166.32) 142.78 (113.30-233.64)
Before CPB-H 2.20 (1.95-2.88) N/A 109.62 (97.50-139.50) N/A
5 1.88 (0.96-2.66) N/A 118.19 (50.40-142.80) N/A
15 2.18 (1.63-2.80) N/A 144.72 (72.90-154.66) N/A
30 2.25 (1.72-2.68) N/A 134.09 (75.15-139.23) N/A
60 2.81 (1.93-3.16) N/A 71.55 (0.00-153.90) N/A
End of CPB-H 2.07 (1.30-2.68) N/A 141.51 (53.7-150.22) N/A
240 1.22 (0.80-2.65) 1.72 (29-5.62) 46.98 (36.54-182.52) 80.10 (47.57-261.96)
End of Surgery 1.40 (0.51-1.69) 1.29 (1.23-1.92) 58.50 (17.28-92.88) 76.11 (55.35-85.17)
5 1.04 (0.83-1.27) 1.02 (0.92-1.26) 54.57 (42.66-67.00) 55.44 (37.74-65.32)
15 0.71 (0.47-27) 0.80 (0.65-1.16) 28.35 (22.26-58.14) 45.43 (35.20-47.85)
30 0.96 (0.61-1.19) 0.91 (0.80-0.97) 43.46 (31.32-69.30) 40.29 (37.83-52.80)
60 0.68 (0.45-0.95) N/A 23.54 (17.08-46.73) N/A
End of TCI 0.87 (0.63-1.12) 0.97 (0.76-1.27) 42.40 (30.09-50.76) 40.95 (37.00-64.77)
5 0.90 (0.64-0.97) 0.78 (0.68-0.86) 44.28 (23.97-48.06) 35.10 (30.81-44.88)
15 0.69 (0.50-0.77) 0.61 (0.45-0.75) 31.95 (19.89 - 38.88) 27.75 (21.83 - 40.26)
30 0.47 (0.37-0.65) 0.51 (0.37-0.59) 21.20 (13.77-29.25) 21.83 (17.11-31.11)
60 0.38 (0.24-0.56) 0.41 (0.33-0.54) 14.84 (9.72-26.55) 19.61 (15.34-30.09)
120 0.26 (0.17-0.41) 0.36 (0.30-0.48) 9.72 (8.16-17.82) 17.76 (13.50-23.46)
240 0.22 (0.12-0.31) 0.31 (0.22-0.37) 6.89 (5.10-13.95) 15.81 (9.45-19.25)
360 0.16 (0.09-0.25) 0.25 (0.19-0.34) 5.30 (4.08-8.64) 13.06 (7.93-17.82)
480 0.13 (0.08-0.17) 0.18 (0.14-0.29) 4.72 (3.17-7.52) 9.18 (6.30-12.65)
720 0.09 (0.05-0.11) 0.14 (0.11-0.22) 4.50 (2.39-5.36) 7.14 (4.84-11.00)
Abbreviations – TCI: target-controlled infusion; CPB-H: on-pump coronary artery bypass grafting; OPCAB: off-pump coronary artery bypass grafting;
N/A: not applicable. Statistics: Mann-Whitney test, significance po0.05.
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and awakening among CPB-H patients relative to OPCAB
patients (Figure 3).
’ DISCUSSION
The bioanalytical method was appropriate for propofol
plasma measurements, particularly because it presented a
wide range of linearity and a high coefficient of linear reg-
ression, illustrating the reliability of the method. A wide
range of linearity was crucial for monitoring both the peak
propofol levels during infusion and the extremely low con-
centrations after cessation of the TCI. In fact, HPLC with
fluorescence detection is commonly reported as a technique
of choice for the quantitative determination of propofol (9).
Furthermore, ultrafiltration was an important addition to
this method, which ultimately enabled separation of the free
and protein-bound propofol in plasma (9,10).
The total propofol plasma levels of both groups were com-
parable during the surgical intervention. However, signifi-
cant increases in the free propofol plasma concentration
(two- to five-fold) were observed in the CPB-H group due
to the CPB-H-induced reduction in drug plasma protein
binding in these patients.
Our data are consistent with the results of previous reports
and revealed that the unbound fraction of propofol in the
blood increased two-fold during CPB (5). The authors of
these previous reports stated that the total concentration of
propofol in the blood remained unchanged after the initia-
tion of normothermic CPB compared with the pre-CPB drug
plasma concentrations. However, the fraction of unbound
propofol in the blood doubled during CPB-H.
The decrease in propofol binding to plasma proteins that
occurred after the initiation of CPB-H resulted in a significant
increase in the fraction of unbound drug in the blood. Similar
studies have also shown that CPB increases the plasma
clearance of anesthetics, mainly due to alteration of the plasma
protein binding of these drugs with albumin and alpha-1
glycoprotein acid (11-13). Propofol mostly binds to albumin
and erythrocyte membranes (14). Hemodilution during CPB
decreases the concentrations of albumin and hematocrit
(4,6,15), leading to an increase in the free fraction of propofol
under CPB-H. Nevertheless, it is assumed that the pharma-
cological effect of propofol ultimately reflects its unbound
Table 3 - Pharmacokinetics of free propofol (medians [quartiles]).
PK- parameters CPB-H OPCAB Statistics (p)
Alpha (h-1) 2.20 (2.07-2.72) 3.89 (3.00-4.34) 0.0010
t(1/2)a (h) 0.32 (0.26-0.34) 0.18 (0.16-0.23) 0.0019
Beta (h-1) 0.13 (0.11-0.16) 0.114 (0.10-0.12) 0.2352
t(1/2)b (h) 5.37 (4.34-6.38) 6.10 (5.74-6.78) 0.3270
VDSS L/kg 14.45 (12.73-18.50) 10.2 (9.90-12.50) 0.0293
CLT mL/min.kg 36.90 (32.77-39.12) 18.97 (14.94-21.38) 0.0070
Abbreviations – CPB: on-pump coronary artery bypass grafting-cardiopulmonary bypass; OPCAB: off-pump coronary artery bypass; N/A: not applicable.
Statistics: Mann-Whitney test, GraphPad Prism v. 5.0, significance po0.05.
Figure 1 - Increases in free drug plasma levels by hypothermic-CPB
(medians [quartiles, min/max values]). Abbreviations – CPB-H:
on-pump coronary artery bypass grafting; OPCAB: off-pump
coronary artery bypass grafting. (’) CPB-H, n=10; (&) OPCAB,
n=9. Statistics: Mann-Whitney test, GraphPad Prism v. 5.0,
significance po0.05.
Figure 2 - Pharmacodynamics modeling using the sigmoid EMAX
model. BIS values versus free propofol plasma levels (medians).
Abbreviations – BIS: Bispectral index; CPB: on-pump coronary
artery bypass grafting; OPCAB: off-pump coronary artery bypass
grafting. (’) CPB, n=10; (&) OPCAB, n=9. GraphPad Prism v. 5.0.
Figure 3 - PK/PD analysis based on the sigmoid EMAX model in the
CPB-H group compared to the OPCAB group. The sigmoid shape
was generated using the medians. BIS axis: Y0=85 in the CPB-H
group versus Y0=95 in the OPCAB group at orotracheal extuba-
tion; EC50=1.12, r
240.90. Abbreviations – BIS: bispectral index;
CPB: on-pump coronary artery bypass grafting; OPCAB: off-pump
coronary artery bypass grafting.
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concentration because only drug that is not bound to plasma
proteins can pass through membranes and reach the effect site
(4). Therefore, the higher concentration of unbound propofol
could explain the significantly lower BIS values observed
in CPB-H patients after TCI cessation (i.e., greater effect)
compared with those found in OPCAB patients. These obser-
vations are consistent with those previously reported in the
literature (4-6,9,15,16).
The PK of free propofol determined based on the two-
compartment open model was significantly altered in
the CPB-H group compared with the OPCAB group due
to the prolonged distribution half-life and the increased
VDSS.
Drug plasma clearance was significantly higher in the
CPB-H group due to the hypothermia associated with CPB-H,
which is supported by the literature (9,14-16). Propofol is
known to be a high-extraction drug, and if drug plasma
binding is reduced, the removal of propofol from the systemic
circulation by the liver can be directly affected. Conse-
quently, in the CPB group, plasma clearance increased due
to heparinization and hemodilution in combination with
CPB-H.
In addition, the kinetic behavior of propofol changes dif-
ferently according to the free drug levels in the CPB-H
group compared with those in the OPCAB group. These
results are consistent with those of Peeters et al. (2008) (17)
and Bienert et al. (2010) (18), who investigated the PK of
propofol in 26 and 28 critical patients, respectively, using
the two-compartment model with NONMEN software.
Subsequently, Wiczling et al. (2012) (19) also demonstrated
the adequacy of the two-compartment model in a study of
the PK of propofol in 10 patients during elective abdominal
aortic surgery.
Regarding the PK/PD approach, the selected sigmoid
EMAX model (variable slope) revealed a strong correlation
between the BIS values and free drug levels (r240.90, po0.001)
in both groups.
Despite the similar total drug plasma levels after propo-
fol infusion cessation, the BIS values in the CPB-H patients
remained lower than those in the OPCAB patients. In fact,
the time to orotracheal intubation was significantly longer in
the CPB-H group than in the OPCAB group (459 min versus
273 min, po0.001) despite similar surgical durations (265 min
for the CPB-H group versus 260 min for the OPCAB group;
p=0.7747). These data are consistent with the reported
results of increases in the drug effect after CPB without
changes in the total drug plasma levels (4,6).
Based on the results of our application of our PK/PD
approach to the free propofol plasma levels, we propose
that the important changes in the PK of propofol induced
by CPB-H described above could explain the increased
post-CPB hypnotic effects observed in patients under-
going CPB-H.
Additionally, the increased depressant effect on the central
nervous system observed in the CPB-H group could be
explained by the increased VDSS and the prolonged distri-
bution half-life as a function of high levels of free propofol in
the systemic circulation, which are associated with the high
free drug concentrations at receptor sites.
In conclusion, the significant increases in the free propofol
plasma concentration in the CPB group were attributed to
the reduction in drug plasma protein binding resulting from
CPB-H, which ultimately led to postoperative alterations in
the PD of propofol.
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